GlassScriptPhysician profile
Shahab Virani
NPI 1033470091
$775.29
in general payments reported to CMS, 2019-2025
13 companies · $47.59 in 2025
The $47.59 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $199 · 2020: $36.32 · 2021: $86.20 · 2022: $186 · 2023: $131 · 2024: $88.70 · 2025: $47.59.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $267.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $267.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $220.08 | 2022-2024 | Rinvoq |
| Astrazeneca Pharmaceuticals LP | $105.78 | 2019-2021 | |
| Glaxosmithkline, LLC. | $91.12 | 2019-2023 | Trelegy Ellipta |
| Genentech USA, INC. | $67.38 | 2021-2022 | |
| Regeneron Pharmaceuticals, INC. | $58.33 | 2019 | |
| Novartis Pharmaceuticals Corporation | $52.46 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.75 | 2021-2022 | |
| Amgen INC. | $46.77 | 2022-2025 | Tezspire |
| Regeneron Healthcare Solutions, INC. | $19.17 | 2023 | Dupixent |
| Pharming Healthcare, INC. | $18.56 | 2022 | |
| Pfizer INC. | $18.24 | 2020 | |
| Circassia INC. | $15.58 | 2019 | |
| Alk-Abello, INC | $14.07 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shahab Virani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.